SCHEMBL5845944

SCHEMBL5845944

Cc1ccc(C)c(N2CC(C(=O)Nc3ccc4c(c3)Cc3ccccc3-4)CC2=O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.55
ALDH1A1 P00352 6/20 0.55
NPSR1 Q6W5P4 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
GFER P55789 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CYP1A2 P05177 2/20 0.47
ADRA2A P08913 1/20 0.47
MAOA P21397 1/20 0.47
SLC6A2 P23975 1/20 0.47
HTR2C P28335 1/20 0.47
SLC6A4 P31645 1/20 0.47
HTR2B P41595 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2C19 P33261 1/20 0.47
THRB P10828 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA4 P22748 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5842239 0.87 MAPT (0.57) MAPTALDH1A1NPSR1SMN1; SMN2THRB
SCHEMBL6609444 0.84 CYP1A2 (0.45) MAPTALDH1A1NPSR1SMN1; SMN2TDP1
SCHEMBL5842134 0.84 GFER (0.54) MAPTALDH1A1NPSR1GFERCYP1A2
SCHEMBL5843822 0.83 CA12 (0.59) MAPTALDH1A1SMN1; SMN2TDP1GAA
SCHEMBL5842505 0.82 MAPT (0.64) MAPTALDH1A1NPSR1SMN1; SMN2CA12
SCHEMBL5842030 0.82 MAPT (0.64) MAPTALDH1A1NPSR1SMN1; SMN2TDP1
SCHEMBL5843367 0.82 MAPT (0.62) MAPTALDH1A1NPSR1SMN1; SMN2THRB
SCHEMBL5841097 0.81 ALDH1A1 (0.58) MAPTALDH1A1NPSR1SMN1; SMN2TDP1
SCHEMBL5841451 0.81 ALDH1A1 (0.69) MAPTALDH1A1NPSR1SMN1; SMN2THRB
SCHEMBL5842097 0.81 MAPT (0.61) MAPTALDH1A1NPSR1SMN1; SMN2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R MAPT 4395/4885ALDH1A1 3034/4885NPSR1 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.